706 results on '"Rajkumar, S V"'
Search Results
2. Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
3. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
4. “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
5. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
6. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
7. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
8. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
9. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
10. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
11. Autologous stem cell transplant for multiple myeloma patients 70 years or older
12. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
13. Natural history of t(11;14) multiple myeloma
14. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma
15. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma
16. P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
17. Second primary malignancies in multiple myeloma: an overview and IMWG consensus
18. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
19. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy
20. Supplement to: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
21. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
22. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
23. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
24. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
25. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
26. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
27. Clarification of the definition of complete response in multiple myeloma
28. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
29. Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma: 36
30. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
31. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
32. Treatment patterns and outcomes in elderly patients with multiple myeloma
33. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
34. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
35. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
36. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
37. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
38. Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance
39. Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies
40. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites
41. Management of treatment-emergent peripheral neuropathy in multiple myeloma
42. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma
43. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
44. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
45. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
46. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
47. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
48. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
49. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
50. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.